Gendicine
AXP000141.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, E1 region replaced by a p53 expression cassette)
- Targets
- TP53
- Originator
- Shenzhen SiBiono GeneTech
- Sponsor
- Shenzhen SiBiono GeneTech
Names
| Name | Type | Source |
|---|---|---|
| Gendicine | preferred name, brand | curator, ncit |
| Genkaxin | brand | ncit |
| rAd-p53 ambiguous | code | ncit |
| Recombinant Adenovirus Encoding p53 ambiguous | synonym | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- E1 region replaced by a human wild-type p53 expression cassette (replication-defective)
- Transgenes
- TP53
- Route
- intratumoral, intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C85485
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| NMPA | CN | 2003-10-16 | approved | Gendicine | Head and neck squamous cell carcinoma, with radiotherapy | source |
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02429037 | P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer | Unknown | Phase 2 | 2015-05 | 2018-12 | 60 | Advanced Head and Neck Cancer |
| NCT02418988 | Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma | Unknown | Phase 2 | 2014-07 | 2017-05 | 120 | Advanced Adult Hepatocellular Carcinoma |
| NCT01574729 | Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma | Unknown | Phase 2 | 2012-08 | 2015-08 | 120 | Non-small Cell Lung Cancer |
| NCT00902122 | rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors | Unknown | Phase 4 | 2009-05 | 2012-08 | 600 | Advanced Malignant Thyroid Tumors |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT00902083 | rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors | Unknown | Phase 4 | 2009-06 | 2012-07 | 600 | Advanced Oral and Maxillofacial Malignant Tumors | name in title: rAd-p53 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41573652 | TACE combined with sorafenib induces complete remission in an elderly patient with hepatocellular carcinoma, hepatic venous tumor thrombus, and diffuse lung metastasis: a case study and literature review. | Frontiers in oncology | 2025 | name in abstract: Gendicine |
| PMID 24457472 | Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma. | American journal of clinical oncology | 2014 | name in abstract: Gendicine |
| PMID 24842203 | [The preliminary study of recombinant adenovirus p53 combined with transarterial embolization with particles for advanced hepatocellular carcinoma]. | Zhonghua yi xue za zhi | 2014 | name in abstract: Gendicine |
| PMID 19882171 | Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. | Journal of cancer research and clinical oncology | 2010 | name in abstract: Gendicine |
| PMID 19318914 | A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization. | Anti-cancer drugs | 2009 | name in abstract: Gendicine |
| PMID 19375021 | Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons | 2009 | name in abstract: Gendicine |
| PMID 15879012 | p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. | Gut | 2005 | name in title: Gendicine |
| PMID 15968745 | Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization. | World journal of gastroenterology | 2005 | name in abstract: Gendicine |
| PMID 16188130 | [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] | 2005 | name in abstract: Gendicine |
Unconfirmed matches (4)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32851960 | Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer. | Current gene therapy | 2020 | name in title: rAd-p53 |
| PMID 26146864 | A patient with a large intrathoracic malignant schwannoma who showed a complete clinical response to rAd-p53-combined with radiotherapy. | Anti-cancer drugs | 2015 | name in title: rAd-p53 |
| PMID 24479409 | Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial. | BMC medicine | 2014 | name in title: rAd-p53 |
| PMID 12082455 | A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. | Cancer gene therapy | 2002 | name in title: rAd-p53 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42248643 | Non-replicating adenoviral vectors for cancer gene therapy. | Advances in cancer research | 2026 | name in abstract: Gendicine |
| PMID 40227707 | Gene and Cell Therapy for Sarcomas: A Review. | Cancers | 2025 | name in abstract: Gendicine |
| PMID 38523676 | Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology. | Genes & diseases | 2024 | name in title: Gendicine |
| PMID 36154608 | Gene Therapy Cargoes Based on Viral Vector Delivery. | Current gene therapy | 2023 | name in abstract: Gendicine |
| PMID 36992407 | Viral Vectors in Gene Therapy: Where Do We Stand in 2023? | Viruses | 2023 | name in abstract: Gendicine |
| PMID 37065938 | Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. | Translational medicine communications | 2023 | name in abstract: Gendicine |
| PMID 37323391 | Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases. | ACS omega | 2023 | name in abstract: Gendicine |
| PMID 38132123 | The Role of p53 in Nanoparticle-Based Therapy for Cancer. | Cells | 2023 | name in abstract: Gendicine |
| PMID 35756634 | Role of Adenoviruses in Cancer Therapy. | Frontiers in oncology | 2022 | name in abstract: Gendicine |
| PMID 34785635 | Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers. | International journal of oral science | 2021 | name in abstract: Gendicine |
| PMID 32528163 | An overview of development in gene therapeutics in China. | Gene therapy | 2020 | name in abstract: Gendicine |
| PMID 32951572 | Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China. | Current gene therapy | 2020 | name in abstract: Gendicine |
| PMID 33013864 | Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. | Frontiers in immunology | 2020 | name in abstract: Gendicine |
| PMID 31933185 | Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. | Pharmaceutical medicine | 2019 | name in abstract: Gendicine |
| PMID 29179583 | Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy. | Human gene therapy | 2018 | name in abstract: Gendicine |
| PMID 29281902 | Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. | Human gene therapy | 2018 | name in title: Gendicine |
| PMID 29334764 | Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside. | Human gene therapy | 2018 | name in abstract: Gendicine |
| PMID 29338444 | The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. | Human gene therapy | 2018 | name in title: Gendicine |
| PMID 29445265 | New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. | Biologics : targets & therapy | 2018 | name in abstract: Gendicine |
| PMID 30305211 | Noninvasive and Local Delivery of Adenoviral-Mediated Herpes Simplex Virus Thymidine Kinase to Treat Glioma Through Focused Ultrasound-Induced Blood-Brain Barrier Opening in Rats. | Journal of biomedical nanotechnology | 2018 | name in abstract: Gendicine |
| PMID 27548881 | The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery. | Expert opinion on drug delivery | 2017 | name in abstract: Gendicine |
| PMID 29018892 | Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives. | Archives of toxicology | 2017 | name in abstract: Gendicine |
| PMID 27843742 | Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis. | SpringerPlus | 2016 | name in abstract: Gendicine |
| PMID 27976709 | Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion. | Scientific reports | 2016 | name in abstract: Gendicine |
| PMID 25496374 | Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors. | Expert opinion on biological therapy | 2015 | name in title: Gendicine |
| PMID 26259388 | Strategies used in the clinical trials of gene therapy for cancer. | Journal of experimental therapeutics & oncology | 2015 | name in abstract: Gendicine |
| PMID 26402250 | Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. | Expert review of anticancer therapy | 2015 | name in abstract: Gendicine |
| PMID 25364261 | Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. | OncoTargets and therapy | 2014 | name in abstract: Gendicine |
| PMID 23840897 | Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. | PloS one | 2013 | name in abstract: Gendicine |
| PMID 24107178 | Advances in adenovirus-mediated p53 cancer gene therapy. | Expert opinion on biological therapy | 2013 | name in abstract: Gendicine |
| PMID 24385699 | Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation. | Chinese journal of cancer research = Chung-kuo yen cheng yen chiu | 2013 | name in title: Gendicine |
| PMID 24385704 | Clinical antiangiogenic effect of recombinant adenovirus-p53 combined with hyperthermia for advanced cancer. | Chinese journal of cancer research = Chung-kuo yen cheng yen chiu | 2013 | name in abstract: Gendicine |
| PMID 22970051 | Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells. | Oncology letters | 2012 | name in abstract: Gendicine |
| PMID 23021247 | Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. | Advances in cancer research | 2012 | name in abstract: Gendicine |
| PMID 21942125 | Updates on current advances in gene therapy. | The West Indian medical journal | 2011 | name in abstract: Gendicine |
| PMID 20679889 | p53 gene therapy for pulmonary metastasis tumor from hepatocellular carcinoma. | Anti-cancer drugs | 2010 | name in abstract: Gendicine |
| PMID 21042759 | Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study. | Oncology reports | 2010 | name in abstract: Gendicine |
| PMID 19508919 | Targeted genetic and viral therapy for advanced head and neck cancers. | Drug discovery today | 2009 | name in abstract: Gendicine |
| PMID 19806503 | An update on gene therapy in China. | Current opinion in molecular therapeutics | 2009 | name in abstract: Gendicine |
| PMID 18465676 | The application of gene therapy in China. | IDrugs : the investigational drugs journal | 2008 | name in abstract: Gendicine |
| PMID 19186869 | [Biologic analysis of recombinant human adenovirus-p53 injection in patients with oral leukoplakia ]. | Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology | 2008 | name in abstract: Gendicine |
| PMID 20021420 | Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. | Current molecular pharmacology | 2008 | name in abstract: Gendicine |
| PMID 17047133 | p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. | Gut | 2006 | name in title: Gendicine |
| PMID 17124301 | Chinese gene therapy. Gendicine's efficacy: hard to translate. | Science (New York, N.Y.) | 2006 | name in title: Gendicine |
| PMID 21144296 | [Effect of recombinant adenovirus-p53 on growth and chemosensitivity of human lung adenocarcinoma cell lines]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer | 2006 | name in abstract: Gendicine |
| PMID 16146351 | DNA-based therapeutics and DNA delivery systems: a comprehensive review. | The AAPS journal | 2005 | name in abstract: Gendicine |
| PMID 16149899 | Gendicine: the first commercial gene therapy product. | Human gene therapy | 2005 | name in title: Gendicine |
| PMID 16149900 | Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. | Human gene therapy | 2005 | name in title: Gendicine |
Unconfirmed matches (10)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32013587 | Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-p53 Combined with Chemotherapy Treatment. | Human gene therapy | 2020 | name in title: rAd-p53 |
| PMID 33060772 | Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. | Scientific reports | 2020 | name in title: rAd-p53 |
| PMID 29328445 | The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma. | Molecular medicine reports | 2018 | name in title: rAd-p53 |
| PMID 30405797 | Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer. | Oncology letters | 2018 | name in title: rAd-p53 |
| PMID 28621316 | Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. | Cancer gene therapy | 2017 | name in title: rAd-p53 |
| PMID 27446369 | Recurrent myoepithelial carcinoma of the submandibular gland treated by rAd-p53 combined with radiotherapy: A case report. | Oncology letters | 2016 | name in title: rAd-p53 |
| PMID 22441128 | Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. | Gene | 2012 | name in title: rAd-p53 |
| PMID 22090785 | rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. | World journal of gastroenterology | 2011 | name in title: rAd-p53 |
| PMID 20678439 | [Experimental studies of rAd-p53 injection by interventional approach for the treatment of rabbit VX2 liver cancer]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology | 2010 | name in title: rAd-p53 |
| PMID 17129471 | [The combination of recombinant rAd-p53 and adriamycin for management of primary drug resistance in chemotherapy of lung squamous cell cancer]. | Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases | 2006 | name in title: rAd-p53 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R21CA241015 | Re-engineered Mitochondrially Targeted p53 Gene Therapy in Liver Cancer | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH | LIM, CAROL S. | 2021–2022 | name in abstract: Gendicine |
Notes
First gene therapy approved anywhere: SFDA (now NMPA) licence 16 October 2003 for head and neck squamous cell carcinoma, launched April 2004. Replication-defective Ad5 with the E1 region replaced by a wild-type human p53 cassette; promoter not verified. Distinct from contusugene ladenovec (AXP000142) and SCH-58500 (AXP000152), which are separate Ad-p53 constructs.
How to cite
Gendicine (AXP000141.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000141.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.